- Home
- WES vs GMAB Comparison
WES vs GMAB Comparison
Compare WES & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WES
- GMAB
- Stock Information
- Founded
- WES 2007
- GMAB 1999
- Country
- WES United States
- GMAB Denmark
- Employees
- WES N/A
- GMAB N/A
- Industry
- WES Natural Gas Distribution
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WES Utilities
- GMAB Health Care
- Exchange
- WES Nasdaq
- GMAB Nasdaq
- Market Cap
- WES 14.9B
- GMAB 15.0B
- IPO Year
- WES 2008
- GMAB N/A
- Fundamental
- Price
- WES $41.59
- GMAB $19.70
- Analyst Decision
- WES Hold
- GMAB Buy
- Analyst Count
- WES 9
- GMAB 8
- Target Price
- WES $38.00
- GMAB $43.00
- AVG Volume (30 Days)
- WES 1.1M
- GMAB 1.3M
- Earning Date
- WES 02-26-2025
- GMAB 02-12-2025
- Dividend Yield
- WES 8.42%
- GMAB N/A
- EPS Growth
- WES 44.12
- GMAB 14.35
- EPS
- WES 3.91
- GMAB 10.80
- Revenue
- WES $3,534,928,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- WES $19.98
- GMAB $32.08
- Revenue Next Year
- WES $2.71
- GMAB $17.51
- P/E Ratio
- WES $10.69
- GMAB $17.58
- Revenue Growth
- WES 16.75
- GMAB 17.75
- 52 Week Low
- WES $27.84
- GMAB $19.02
- 52 Week High
- WES $43.33
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- WES 56.85
- GMAB 38.48
- Support Level
- WES $40.62
- GMAB $19.02
- Resistance Level
- WES $42.38
- GMAB $19.86
- Average True Range (ATR)
- WES 1.08
- GMAB 0.45
- MACD
- WES 0.02
- GMAB -0.19
- Stochastic Oscillator
- WES 59.47
- GMAB 17.73
About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests
Western Midstream Partners LP is a US-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.